Drug intelligence / Profile preview

Sanzi Fang

Development stage: Preclinical
Lead developer: Nanjing University of Chinese Medicine
Administration: Oral

Overview

Sanzi Fang (SZF) is a Traditional Chinese Medicine (TCM) herbal compound that has been investigated for its potential in the prevention and treatment of colorectal adenoma (CRA). Research, primarily in preclinical mouse models, suggests that SZF exerts its therapeutic effects by modulating the intestinal flora and improving colorectal metabolic profiles. It has been observed to increase beneficial gut bacteria and decrease harmful ones, as well as normalize various colorectal metabolites. This traditional formula is being explored for its ability to prevent the progression of CRA to cancer.

Other names: SZF三子方三子方颗粒剂模拟剂Sanzi formula

Targets

MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR T790M (Epidermal growth factor receptor T790M mutant)

Beyond the preview

Go deeper on Sanzi Fang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanzi Fang.

Explore the full profile